toxylact: a06ab08 sodium picosulfate

The first professional lActological database in the word

Sodium picosulfate (ATC A06AB08) is a locally acting stimulant laxative considered compatible with breastfeeding, with negligible transfer into breast milk and no need for routine interruption of lactation when used appropriately.medpedia.framar+3

Pharmacological class and indications

ATC class A06AB08 includes sodium picosulfate, a triarylmethane‑derivative stimulant (contact) laxative acting primarily in the colon. It is indicated for short‑term relief of functional constipation and, in combination with magnesium oxide and citric acid, for bowel cleansing prior to colonoscopy. In routine practice, oral drops or tablets are used intermittently for constipation, while bowel‑prep combinations are restricted to procedural settings under medical supervision.hpra+5

Mechanism of action and pharmacokinetics

Sodium picosulfate is a prodrug that is hydrolyzed by colonic bacteria to its active metabolite bis-(p‑hydroxyphenyl)-pyridyl‑2‑methane (BHPM), which stimulates colonic mucosa and enhances peristalsis. Systemic absorption from the gastrointestinal tract is minimal, leading to very low plasma concentrations and undetectable levels in breast milk in available studies. The onset of laxative effect typically occurs within about 6–12 hours after administration, consistent with overnight dosing to induce morning defecation.ncbi.nlm.nih+9

Therapeutic use, dosage and contraindications

Oral sodium picosulfate is used as a short‑course stimulant laxative in adults and older children, with typical doses of 5–10 mg at bedtime. National product information emphasizes limiting daily use to a few days and reducing or stopping treatment once bowel regularity is restored to avoid dependence and electrolyte disturbances. Contraindications include ileus or intestinal obstruction, acute abdominal surgical conditions (such as appendicitis), inflammatory bowel disease, gastrointestinal ulceration or perforation, severe abdominal pain with nausea/vomiting, severe dehydration and known hypersensitivity. Use is generally restricted or not recommended in very young children, with lower age cut‑offs defined in specific product summaries of characteristics.breastfeedingnetwork+5

Adverse effects and toxicological profile

Common adverse effects include abdominal cramps, colicky pain and diarrhea; allergic reactions have also been reported. Overdose or prolonged high‑dose use may lead to marked diarrhea with clinically significant loss of potassium and other electrolytes, potentially causing dehydration and associated arrhythmogenic risk. As with other stimulant laxatives, chronic inappropriate use can contribute to laxative dependence and impaired natural bowel motility, so treatment courses should remain short and indication‑driven. Overall, the toxicological profile in adults is well characterized, and serious toxicity is uncommon when used in line with product guidance and with attention to fluid and electrolyte balance.hpra+5

Lactation safety and lactological considerations

Lactation data (LactMed, lactation guidelines and specialized breastfeeding pharmacology reviews) indicate that sodium picosulfate can be taken during breastfeeding with no special precautions required in healthy term infants. The negligible oral bioavailability and failure to detect the active metabolite in breast milk underpin its classification as compatible or very low risk in breastfeeding safety databases. Professional breastfeeding resources describe stimulant laxatives (including sodium picosulfate) as suitable for occasional use in lactating women, while recommending bulk‑forming or osmotic laxatives as first‑line options for chronic constipation. When sodium picosulfate is used, expert guidance advises the lowest effective dose for the shortest period, with routine clinical monitoring of the breastfed infant for gastrointestinal symptoms such as loose stools, although clinically significant effects are rarely reported.sps+6

Clinical positioning in lactating patients

In lactating patients with simple constipation, non‑pharmacological measures (dietary fiber, fluid intake, physical activity) remain foundational, and bulk or osmotic laxatives are preferred for regular use. Sodium picosulfate is a second‑line or adjunct option reserved for situations requiring rapid, short‑term stimulation of bowel motility, or when other laxatives are ineffective or contraindicated. In bowel‑prep regimens containing sodium picosulfate, most guidelines allow use during breastfeeding, with individualized risk–benefit assessment and consideration of maternal procedural needs, the brief exposure window and the low infant dose via milk. Across these scenarios, breastfeeding can usually continue without interruption, provided the mother is otherwise clinically stable and the infant is term and healthy.drugs.ncats+6

Recent ARTICLES

July 24

Abdominal Compartment Syndrome

PWhile the formal term and its consensus definitions were codified by the World Society of the Abdominal Compartment Syndrome (WSACS) only in the early 2000s, the physiological underpinnings have been observed for over 150 years. In 1863, the French physiologist Etienne-Jules Marey was the first to document the reciprocal relationship between intra-abdominal pressure (IAP) and respiratory function, noting that the expansion of the abdominal cavity directly impacted the efficiency of the thoracic bellows.

July 18

Assessment of Postoperative Fever

For the physician and the student of medicine, the assessment of postoperative fever is not merely a task of temperature monitoring, but a diagnostic journey that requires a nuanced understanding of immunology, physiology, and clinical timing. Guided by the principle of "Primum non nocere," this report seeks to bridge the gap between complex pathophysiological mechanisms and the empathetic care of the patient, providing a comprehensive framework for identifying, understanding, and managing this common clinical challenge.

July 14

Clinical Review of Congenital and Acquired Cystic Kidney Diseases

The healing arts, as envisioned by the ancient traditions of medicine, seek not merely the eradication of pathology but the restoration of a delicate equilibrium between the body’s internal environment and the external world. In the realm of nephrology, cystic diseases of the kidney represent a profound disruption of this balance.

Spotlight

A Comprehensive Analysis of Complement System Deficiencies in Pediatric and Adult Populations

The human immune system is a tapestry of ancient evolutionary mechanisms and highly specialized adaptive responses, woven together to maintain the delicate equilibrium of health. At the heart of this architecture lies the complement system, a complex network of over fifty proteins that function as the primordial vanguard of innate immunity. Named for its ability to "complement" the action of antibodies, this system serves as a bridge between the immediate, non-specific recognition of pathogens and the targeted, long-term memory of the adaptive immune response. However, when this sentinel falls silent due to genetic or acquired deficiencies, the result is a state of nuanced immunosuppression that significantly alters the human clinical landscape across all ages.